Clinical use of factor VIII and factor IX concentrates.
作者信息
Morfini Massimo, Coppola Antonio, Franchini Massimo, Di Minno Giovanni
机构信息
Agency for Haemophilia, Department of Emergency and Reception, Careggi University Hospital, Florence, Italy.
Regional Reference Centre for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
出版信息
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
Abstract
摘要
相似文献
1
Clinical use of factor VIII and factor IX concentrates.凝血因子VIII和凝血因子IX浓缩物的临床应用。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s55-63. doi: 10.2450/2013.010s.
2
Prophylaxis for adults with haemophilia: one size does not fit all.成人血友病的预防：一种方法并不适用于所有人。
Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11.
3
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.IX因子缺乏症患者与VIII因子缺乏症患者治疗情况的比较：作为国际IX因子治疗网络一部分开展的一项国际调查结果
Haemophilia. 2014 Sep;20(5):e362-4. doi: 10.1111/hae.12487. Epub 2014 Aug 25.
4
Prophylaxis in haemophilia should be life-long.血友病的预防应该是终身的。
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
5
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.对凝血因子 VIII、凝血因子 IX 的需求以及凝血因子浓缩物产品过剩管理。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
6
7
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.在常规临床实践中使用延长半衰期的凝血因子浓缩物：英国血液学标准委员会的指南
Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.
8
Maintenance of treatment logs by haemophilia patients.血友病患者治疗日志的记录
Haemophilia. 2010 May;16(3):545-7. doi: 10.1111/j.1365-2516.2009.02169.x. Epub 2009 Dec 29.
9
[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].[活化凝血酶原复合物（FEIBA）对伴有Ⅷ或Ⅸ因子抑制物的血友病患者的临床疗效]
Nihon Ketsueki Gakkai Zasshi. 1982 Sep;45(5):987-92.
10
Sodium content in products used to treat haemophilia.用于治疗血友病的产品中的钠含量。
Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26.
引用本文的文献
1
Nonfactor Therapies in Hemophilia A: An Essential Drug Entity.甲型血友病的非凝血因子疗法：一种重要的药物实体。
Cureus. 2024 Oct 3;16(10):e70763. doi: 10.7759/cureus.70763. eCollection 2024 Oct.
2
Pain in Hemophilia: Unexplored Role of Oxidative Stress.血友病中的疼痛：氧化应激未被探索的作用
Antioxidants (Basel). 2022 Jun 3;11(6):1113. doi: 10.3390/antiox11061113.
3
Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection.应对免疫球蛋白短缺：基于循证和数据收集的合理化计划。
Front Public Health. 2022 May 19;10:893770. doi: 10.3389/fpubh.2022.893770. eCollection 2022.
4
In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.计算机模拟评估个体化延长半衰期因子 IX 浓缩物剂量在乙型血友病患者中的有限采样策略。
Eur J Clin Pharmacol. 2022 Feb;78(2):237-249. doi: 10.1007/s00228-021-03173-2. Epub 2021 Oct 15.
5
Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.血友病常规临床实践中的药代动力学：原理与模式——实践综述
Ther Adv Hematol. 2020 Oct 20;11:2040620720966888. doi: 10.1177/2040620720966888. eCollection 2020.
6
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia.血友病中凝血因子浓缩物和去氨加压素的群体药代动力学。
Clin Pharmacokinet. 2021 Jan;60(1):1-16. doi: 10.1007/s40262-020-00936-5.
7
Supramolecular Aptamers on Graphene Oxide for Efficient Inhibition of Thrombin Activity.用于高效抑制凝血酶活性的氧化石墨烯上的超分子适配体
Front Chem. 2019 May 16;7:280. doi: 10.3389/fchem.2019.00280. eCollection 2019.
8
Hemophilia trials in the twenty-first century: Defining patient important outcomes.21世纪的血友病试验：确定对患者重要的结局
Res Pract Thromb Haemost. 2019 Mar 12;3(2):184-192. doi: 10.1002/rth2.12195. eCollection 2019 Apr.
9
Mutation Spectrum and Genotype-Phenotype Analyses in a Pakistani Cohort With Hemophilia B.巴基斯坦B型血友病队列中的突变谱及基因型-表型分析
Clin Appl Thromb Hemost. 2018 Jul;24(5):741-748. doi: 10.1177/1076029617721011. Epub 2017 Jul 28.
10
Definition of an organisational model for the prevention and reduction of health and social impacts of inherited bleeding disorders.预防和减少遗传性出血性疾病对健康和社会影响的组织模式定义。
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s582-8. doi: 10.2450/2014.0087-14s.
本文引用的文献
1
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.意大利血友病治疗者对方案和产品选择的认知挑战和态度：2013 年 AICE 调查。
Haemophilia. 2014 Mar;20(2):e128-35. doi: 10.1111/hae.12334.
2
Defining severity of hemophilia: more than factor levels.定义血友病的严重程度：不仅仅是因子水平。
Semin Thromb Hemost. 2013 Oct;39(7):702-10. doi: 10.1055/s-0033-1354426. Epub 2013 Sep 11.
3
Tailored versus standard dose prophylaxis in children with hemophilia A.血友病 A 患儿的个体化与标准剂量预防治疗。
Semin Thromb Hemost. 2013 Oct;39(7):711-22. doi: 10.1055/s-0033-1354419. Epub 2013 Sep 10.
4
Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.系统评价 FVIII 浓缩物在既往未治疗的重度血友病 A 患者抑制剂发展中的作用：2013 年更新。
Semin Thromb Hemost. 2013 Oct;39(7):752-66. doi: 10.1055/s-0033-1356715. Epub 2013 Sep 10.
5
Hemophilia a and hemophilia B: different types of diseases?血友病 A 和血友病 B：不同类型的疾病？
Semin Thromb Hemost. 2013 Oct;39(7):697-701. doi: 10.1055/s-0033-1353996. Epub 2013 Sep 8.
6
Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities.综合性血友病护理中的新问题：预防、识别和监测与年龄相关的合并症。
Semin Thromb Hemost. 2013 Oct;39(7):794-802. doi: 10.1055/s-0033-1354424. Epub 2013 Sep 8.
7
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.一种新型无血浆制备方法的重组人血管性血友病因子的药代动力学和安全性：前瞻性临床试验。
Blood. 2013 Aug 1;122(5):648-57. doi: 10.1182/blood-2013-01-479527. Epub 2013 Jun 18.
8
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates.在接受血浆源性凝血因子浓缩物治疗的出血性疾病患者中，细小病毒B19持续传播的证据。
Transfusion. 2013 May;53(5):1143-4. doi: 10.1111/trf.12153.
9
Treatment of hemophilia B: focus on recombinant factor IX.乙型血友病的治疗：聚焦于重组凝血因子IX。
Biologics. 2013;7:33-8. doi: 10.2147/BTT.S31582. Epub 2013 Feb 12.
10
Factor VIII products and inhibitor development in severe hemophilia A.VIII 因子产品与严重甲型血友病抑制物的产生。
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
Zotero 插件